Small Molecule STAT Inhibitors as New Cancer Treatments

6 September 2017

In this video, Professor Patrick Gunning, University of Toronto Mississauga, discusses his work developing small molecule inhibitors for STAT proteins, with the aim of developing new cancer treatments. STAT-3 is found to be hyperactive in over 70% of human cancer, leading to uncontrolled cell growth, whilst STAT-5 has recently been identified as a target in haematological oncology. The Cytation™ Cell Imaging Multi-Mode Reader by BioTek Instruments, Inc. has been an invaluable instrument within the Gunning laboratory. Learn how it has helped to accelerate drug discovery by enabling the identification of many promising small molecules in pre-clinical trials.